ERBB2 and breast carcinoma: Further analysis of FABP5 expression in tumor cells across different breast cancer subtypes demonstrated that both triple negative (108.33 ± 76.36, H-score) and HER2+ (108.33 ± 80.70, H-score) subtypes exhibited significantly higher levels of FABP5 expression (p < 0.0001) compared to the hormone sensitive subtype (29.76 ± 37.41, H-score) (Fig. 5G).